AR076974A1 - Metodo para sintetizar pirfenidona - Google Patents

Metodo para sintetizar pirfenidona

Info

Publication number
AR076974A1
AR076974A1 ARP100101971A ARP100101971A AR076974A1 AR 076974 A1 AR076974 A1 AR 076974A1 AR P100101971 A ARP100101971 A AR P100101971A AR P100101971 A ARP100101971 A AR P100101971A AR 076974 A1 AR076974 A1 AR 076974A1
Authority
AR
Argentina
Prior art keywords
pirfenidone
bromobenzene
dibromobenzene
butanol
methyl
Prior art date
Application number
ARP100101971A
Other languages
English (en)
Inventor
Michael John Cyr
Sabine Marie-Francoise Brigitte Boutet
Ramachandran Radhakrishnan
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43298478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076974(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of AR076974A1 publication Critical patent/AR076974A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Cardiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un proceso para sintetizar pirfenidona a partir de bromobenceno con menos de aproximadamente 0,15% en peso de dibromobenceno. También, procesos para sintetizar pirfenidona sin usar acetato de etilo o n-butanol, y pirfenidona con niveles controlados de acetato de etilo, n-butanol, di(5-metil-2-piridinona)bencenos, y otras impurezas con los tiempos de retencion que se especifican. También, formas de dosificacion que se formulan incluyendo la pirfenidona que se divulga. Reivindicacion 1: Un método para sintetizar pirfenidona caracterizado porque comprende mezclar bromobenceno, 5-metil-2-piridona, oxido cuproso, y un solvente orgánico en condiciones suficientes para formar pirfenidona, donde el bromobenceno comprende menos de aproximadamente 0,15% en peso o como proporcion molar, de dibromobenceno.
ARP100101971A 2009-06-03 2010-06-03 Metodo para sintetizar pirfenidona AR076974A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18358809P 2009-06-03 2009-06-03

Publications (1)

Publication Number Publication Date
AR076974A1 true AR076974A1 (es) 2011-07-20

Family

ID=43298478

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101971A AR076974A1 (es) 2009-06-03 2010-06-03 Metodo para sintetizar pirfenidona

Country Status (35)

Country Link
US (6) US20110003863A1 (es)
EP (1) EP2440543B1 (es)
JP (2) JP5848244B2 (es)
KR (1) KR101734858B1 (es)
CN (1) CN102482255A (es)
AP (1) AP3630A (es)
AR (1) AR076974A1 (es)
AU (1) AU2010256693B2 (es)
BR (1) BRPI1011015B8 (es)
CA (1) CA2764043C (es)
CL (1) CL2011003069A1 (es)
DK (1) DK2440543T3 (es)
EA (1) EA021826B1 (es)
ES (1) ES2538103T3 (es)
GE (1) GEP20156223B (es)
HN (1) HN2011003187A (es)
HR (1) HRP20150696T1 (es)
HU (1) HUE026014T2 (es)
IL (1) IL216565A (es)
MA (1) MA33489B1 (es)
MX (1) MX2011012654A (es)
MY (1) MY162443A (es)
NI (1) NI201100211A (es)
NZ (1) NZ596872A (es)
PE (1) PE20120398A1 (es)
PL (1) PL2440543T3 (es)
PT (1) PT2440543E (es)
RS (1) RS54031B1 (es)
SG (1) SG176648A1 (es)
SI (1) SI2440543T1 (es)
TN (1) TN2011000615A1 (es)
TW (1) TWI434833B (es)
UA (1) UA106759C2 (es)
WO (1) WO2010141600A2 (es)
ZA (1) ZA201108794B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US10092552B2 (en) 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
NZ722927A (en) 2014-01-10 2022-07-29 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
EA201790391A1 (ru) * 2014-08-15 2017-06-30 Пиксарбайо Корпорейшн Композиции для ингибирования воспаления у субъекта с повреждением спинного мозга и способы их применения
EP3307714A1 (en) 2015-01-26 2018-04-18 Ulkar Kimya Sanayii Ve Ticaret A. S. An improved method for the synthesis and purification of pirfenidone
ITUB20154832A1 (it) 2015-10-29 2017-04-29 Procos Spa Processo per la sintesi di pirfenidone
CN105315198A (zh) * 2015-11-02 2016-02-10 重庆康乐制药有限公司 一种吡非尼酮的晶型及其制备方法
CN105330598B (zh) * 2015-12-02 2017-11-14 新发药业有限公司 一种吡非尼酮的制备方法
US11066368B2 (en) 2016-01-14 2021-07-20 Laurus Labs Limited Process for the preparation and particle size reduction of pirfenidone
WO2017122139A1 (en) * 2016-01-14 2017-07-20 Laurus Labs Limited An improved process for the preparation of pirfenidone
WO2017130166A1 (en) * 2016-01-31 2017-08-03 Granules India Limited An improved process for the preparation of highly pure anti-fibrotic drug
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
IT201600108927A1 (it) * 2016-10-27 2018-04-27 Dipharma Francis Srl Metodo per sintetizzare un farmaco antifibrotico
IT201600071672A1 (it) * 2016-07-08 2018-01-08 Dipharma Francis Srl Metodo per sintetizzare un farmaco immunosoppressore
US20180009753A1 (en) * 2016-07-08 2018-01-11 Dipharma Francis S.R.L. Method for preparing an antifibrotic agent
WO2018083709A1 (en) * 2016-11-07 2018-05-11 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of pure 5-methyl-1-phenyl-2-1 (h)-pyridone
WO2018178996A1 (en) * 2017-03-28 2018-10-04 Natco Pharma Limited Improved process for the preparation of pirfenidone
US20200165203A1 (en) 2017-07-31 2020-05-28 Washington University Use of pirfenidone and derivatives for modulation of b lymphocyte activity and organ protection from acute tissue damage
ES2886152T3 (es) 2017-12-11 2021-12-16 Laurus Labs Ltd Un procedimiento mejorado para la preparación de pirfenidona
CN112409246B (zh) * 2019-08-21 2023-04-07 北京凯因科技股份有限公司 一种吡非尼酮的晶型及其制备方法
CN115666533A (zh) * 2020-04-22 2023-01-31 永进药品工业株式会社 具有改善的安全性和稳定性的含吡非尼酮的肠溶包衣制剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
JPH06505239A (ja) * 1991-01-31 1994-06-16 ワーナー−ランバート・コンパニー 抗炎症剤として有用な４，６−ジ−第三ブチル−５−ヒドロキシ−１，３−ピリミジンの置換されたヘテロアリール類似体
JPWO2002085858A1 (ja) * 2001-04-20 2004-08-12 旭硝子株式会社 精製されたピペリジン誘導体の製造方法
WO2003014087A1 (fr) * 2001-08-06 2003-02-20 Asahi Glass Company, Limited Procede de preparation de 5-methyl-1-phenyl-2(1h)-pyridinone
CN1218942C (zh) 2002-06-11 2005-09-14 中南大学湘雅医学院 抗纤维化吡啶酮化合物及其生产工艺方法
CN100396669C (zh) * 2006-03-15 2008-06-25 浙江省医学科学院 一种抗纤维化药物吡非尼酮的制备方法
MX2007006349A (es) * 2007-05-29 2009-02-18 Cell Therapy And Technology S Nuevo proceso de sintesis para la obtencion de 5-metil-1-fenil-2-(ih)-piridona, composicion y uso de la misma.
NZ599643A (en) * 2007-06-20 2013-11-29 Auspex Pharmaceuticals Inc Substituted N-aryl pyridinones as fibrotic inhibitors
WO2009035598A1 (en) * 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone

Also Published As

Publication number Publication date
AU2010256693A1 (en) 2012-01-12
KR20120016277A (ko) 2012-02-23
BRPI1011015A2 (pt) 2018-02-14
US20110003863A1 (en) 2011-01-06
PT2440543E (pt) 2015-07-03
SI2440543T1 (sl) 2015-06-30
CL2011003069A1 (es) 2012-05-25
US20120016133A1 (en) 2012-01-19
WO2010141600A2 (en) 2010-12-09
TN2011000615A1 (en) 2013-05-24
TWI434833B (zh) 2014-04-21
NZ596872A (en) 2013-12-20
CN102482255A (zh) 2012-05-30
US20140221660A1 (en) 2014-08-07
US8519140B2 (en) 2013-08-27
MY162443A (en) 2017-06-15
EA021826B1 (ru) 2015-09-30
IL216565A0 (en) 2012-03-01
SG176648A1 (en) 2012-01-30
NI201100211A (es) 2012-08-01
IL216565A (en) 2015-06-30
PE20120398A1 (es) 2012-05-13
HRP20150696T1 (hr) 2015-08-28
EP2440543A4 (en) 2012-11-21
EP2440543A2 (en) 2012-04-18
KR101734858B1 (ko) 2017-05-12
MA33489B1 (fr) 2012-08-01
PL2440543T3 (pl) 2015-09-30
AP3630A (en) 2016-03-08
BRPI1011015B8 (pt) 2021-05-25
US20130345430A1 (en) 2013-12-26
CA2764043A1 (en) 2010-12-09
AU2010256693B2 (en) 2015-09-17
EP2440543B1 (en) 2015-04-15
ZA201108794B (en) 2013-03-27
WO2010141600A3 (en) 2011-04-21
BRPI1011015B1 (pt) 2020-11-10
US20150368200A1 (en) 2015-12-24
CA2764043C (en) 2018-01-16
HN2011003187A (es) 2015-02-02
EA201101695A1 (ru) 2012-05-30
UA106759C2 (uk) 2014-10-10
DK2440543T3 (en) 2015-05-18
AP2012006052A0 (en) 2012-02-29
US20150065720A1 (en) 2015-03-05
JP5848244B2 (ja) 2016-01-27
JP2016026196A (ja) 2016-02-12
RS54031B1 (en) 2015-10-30
HUE026014T2 (en) 2016-05-30
GEP20156223B (en) 2015-01-26
ES2538103T3 (es) 2015-06-17
TW201043602A (en) 2010-12-16
JP2012528877A (ja) 2012-11-15
MX2011012654A (es) 2012-01-12

Similar Documents

Publication Publication Date Title
AR076974A1 (es) Metodo para sintetizar pirfenidona
EA201491146A1 (ru) Способ извлечения карбоновой кислоты из водного раствора
CO6541539A2 (es) Procesos para preparar las formas cristalinas a y b de ilaprazol y proceso para convertir las formas cristalinas
BR112014008473A2 (pt) processo para a redução da perda de amônia e odor de material orgânico ou resíduo para a atmosfera, solução de nitrato ácida e instalação para a redução da perda de amônia
CU20120137A7 (es) Hidrato del hidrocloruro de agomelatina y preparación de éste
MX2007010141A (es) Procesos para la preparacion de intermedios de linezolid.
MX2013014421A (es) Procedimiento para la preparacion de una composicion que comprende complejos metalicos en una matriz organica aceitosa.
AR085052A1 (es) Metodos para producir un compuesto profarmaco inhibidor de la union al vih e intermediarios
IN2015MN00013A (es)
AR117002A2 (es) Proceso para la preparación de inhibidores de quinasa c-fms
CL2019000016A1 (es) Procesos novedosos para preparar estimuladores de guanilato ciclasa soluble.
DK1907396T3 (da) Fremgangsmåde til fremstilling af 4-beta-amino-4'-demethyl-4-deoxypodophyllotoxin
GB201204023D0 (en) Process for producing V-Coelenterazine compounds
IN2015DN01009A (es)
AR081804A1 (es) Composicion de control de fitoenfermedades y metodo para controlar fitoenfermedades
PH12014501704A1 (en) Method for preparing compound by novel michael addition reaction using water or various acids as additive
AR082775A1 (es) Formulaciones de fumarato
AR074151A1 (es) Un derivado de benzoilbencenoacetamida, proceso de preparacion del mismo, forma polimorfica b de dicho compuesto, proceso de obtencion de dicha forma polimorfica b y su uso
PH12016500749A1 (en) A method for preparing an intermediate of iopromide
MY177491A (en) Method for producing monoglyceride-containing composition
CL2012001528A1 (es) Proceso para preparar la forma cristalina a de ilaprazol a partir de una sal inorganica de ilaprazol y posterior neutralizacion de la sal con un acido en un solvente de reaccion; y proceso para preparar la forma cristalina b de ilaprazol en la forma cristalina a de ilaprazol.
UA123716U (uk) Обетіхолева кислота
PL411433A1 (pl) Sposób wytwarzania 5-alkilosalicylaldoksymów i zastosowanie
AR084946A1 (es) Procedimiento de preparacion de metaxalona
PL420085A1 (pl) Sposób wytwarzania 3-n-butylo-4,7-dihydroftalidu

Legal Events

Date Code Title Description
FG Grant, registration